QUIDEL CORPORATION (NASDAQ:QDEL) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition
Annual J.P. Morgan Healthcare Conference on Wednesday, January 10,
2017, the company is providing preliminary unaudited revenue
results for its fourth quarter of 2016. Based on preliminary
financial information, Quidel expects revenues in the fourth
quarter of 2016 to be between $52 million and $53 million.
of operations for the quarter ended December 31, 2016. The company
expects to issue full financial results for the fourth quarter and
fiscal year 2016 in February.
revenue results for the quarter ended December 31, 2016 on January
6, 2017. A copy of the press release is attached as Exhibit 99.1 to
this current report on Form 8-K.
this Form 8-K reflects the companys current preliminary revenue
estimates, is subject to the completion of its audit process, and
is subject to change. The companys full fourth quarter and year
2016 results could differ materially from the preliminary estimates
provided in this Form 8-K. You are cautioned not to place undue
reliance on these forward-looking statements, which reflect
managements analysis only as of the date of this Form 8-K. We
undertake no obligation to publicly release the results of any
revision or update of the forward-looking statements, except as
required by law.
at the 35th Annual J.P. Morgan Healthcare Conference on January 10,
2017, the company is reporting Sofia instrument placements of
approximately 17,500 placements at customer sites as of January 6,
2017.
|
|
|
|
|
|
|
|
|
(d) Exhibits.
|
|
|||
|
|
|
|
|||
|
|
The following exhibit is furnished with this current
report on Form 8-K: |
|
|||
|
|
|
|
|||
|
|
Exhibit Number
|
Description of Exhibit
|
|||
|
|
|
|
|
|
|
|
|
99.1
|
Press release, dated January 6, 2017
|
|||
|
|
|
|
|
|
|
About QUIDEL CORPORATION (NASDAQ:QDEL)
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. The Company’s diagnostic testing solutions primarily include applications in infectious diseases, women’s health and gastrointestinal diseases. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics and wellness screening centers. It markets its products in the United States through a network of national and regional distributors and a direct sales force. Internationally, it sells and markets primarily through distributor arrangements. Its diagnostic solutions are used in the detection and diagnosis of many critical diseases and other medical conditions, including autoimmune diseases, bone health and thyroid diseases. It provides diagnostic testing solutions under various brand names, including Quidel, QuickVue+ and Thyretain. QUIDEL CORPORATION (NASDAQ:QDEL) Recent Trading Information
QUIDEL CORPORATION (NASDAQ:QDEL) closed its last trading session down -0.13 at 20.39 with 253,902 shares trading hands.